Dr. Oliver Sartor is medical oncologist and translational researcher with a special focus on prostate cancer over the past 33 years. He is currently Professor of Medical Oncology at the Mayo Clinic. His scholarly output includes more than 500 peer-review publications and he has led multiple national and international advanced prostate cancer trials including those pivotal for FDA approval with samarium-153, cabazitaxel, radium-223, and Lu-177-PSMA-617. These trials have been practice-changing and have helped to shape the current therapeutic landscape in advanced and castration-resistant prostate cancer.

In addition to scholarly work, he has served in a variety of academic leadership positions. At the Mayo Clinic, he is Director of Radiopharmaceutical Trials and was recently appointed as Chief of the Genitourinary (GU) Cancer Disease Group. Prior to that at the Tulane University School of Medicine, he was the Associate Dean for Oncology and Medical Director of the Tulane Cancer Center. He served multiple terms on the Department of Defense (DOD) Prostate Cancer Integration Panel and was a past-Chairman of that committee. He also served a 5-year term on the Board of Scientific Counselors (Clinical and Epidemiology) at the National Cancer Institute.

He has served on numerous guideline and consensus committees including those convened by the AUA, AJCC, APCCC, and the Prostate Cancer Working Group (PCWG3/4) and has served as an ad-hoc consultant to the FDA and MEDCAC.